NewslettersMuscle Cell News PepGen Receives US FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy By Noshin Noorjahan - March 18, 2024 0 PepGen Inc. announced that the US FDA granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy. [PepGen Inc.] Press Release